

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Assessment Programme

Quantitative faecal immunochemical tests to assess symptomatic people who are at low risk of colorectal cancer in primary care

### Stakeholder list

<b>Manufacturer(s)</b> Alpha Laboratories MAST Group Ltd R-Biopharm Rhône Ltd Sysmex UK Ltd
<b>Manufacturer(s) of related technologies (not included in scope)</b> BIOHIT Healthcare Ltd DiaSorin Ltd Origin Sciences Ltd
<b>Professional groups</b> Institute of Biomedical Science Royal College of Pathologists Royal College of Physicians Royal College of Nursing
<b>Patient/carer groups</b> Beating Bowel Cancer Bowel Cancer UK
<b>Research groups</b> Cancer Research UK
<b>Associated guideline groups</b> None
<b>External Assessment Group</b> Kleijnen Systematic Reviews
<b>Others</b> British In Vitro Diagnostics Association Birmingham Quality (UK NEQAS) Department of Health Healthcare Improvement Scotland NHS England Welsh Government

**Definitions:****Stakeholders**

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

**External Assessment Group (EAG)**

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).